| Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More | Frank Vinluan | 09/25/20 | National |
| Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue | Frank Vinluan | 09/09/20 | National |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Clinical Trial Diversity Isn’t Just a Moral Issue–It’s a Scientific Imperative | Liz Beatty | 07/27/20 | National |
| Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug | Frank Vinluan | 06/05/20 | New York |
| From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq | Frank Vinluan | 05/15/20 | New York |
| BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info | Frank Vinluan | 05/13/20 | New York |
| CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas | Frank Vinluan | 03/24/20 | San Francisco |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
| Sanofi Wins FDA Nod for Combo Therapy in Multiple Myeloma | Sarah de Crescenzo | 03/03/20 | National |
| Xilio Unveils New Name, $100M to Bring Targeted Cancer Drugs to Clinic | Frank Vinluan | 03/02/20 | Boston |
| Allogene, SpringWorks to Test Drug Combo in Multiple Myeloma Trial | Sarah de Crescenzo | 01/13/20 | San Francisco |
| Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More | Frank Vinluan | 11/22/19 | National |
| Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More | Alex Lash | 08/30/19 | National |
| Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight | Ben Fidler | 08/28/19 | New York |
| GSK’s Cancer Comeback Continues With Data for Multiple Myeloma Drug | Frank Vinluan | 08/23/19 | National |
| Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs | Frank Vinluan | 08/16/19 | New York |
| Bio Roundup: Duchenne Race, Warren v. Gottlieb, A $599 Genome & More | Ben Fidler | 07/05/19 | National |
| Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More | Frank Vinluan | 04/26/19 | National |
| The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski | Ben Fidler | 03/11/19 | National |
| Bristol-Myers’ $74B Celgene Buyout Faces Opposition from Wellington | Frank Vinluan | 02/27/19 | New York |
| FDA Staff Hammers Karyopharm Cancer Drug on Safety, Efficacy Concerns | Frank Vinluan | 02/22/19 | Boston |
| AbbVie Joins Myeloma Race with $90M Deal for Rights to Teneobio Drug | Frank Vinluan | 02/11/19 | San Francisco |
| Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More | Ben Fidler | 02/08/19 | National |
| Aduro Biotech Slashes Staff 37%, Turns Focus to Lead Cancer Drugs | Frank Vinluan | 01/30/19 | San Francisco |
| Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments | Sarah de Crescenzo | 01/04/19 | San Diego |
| In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B | Ben Fidler | 01/03/19 | National |
| 15 for ’19: Key Clinical Data to Watch for Next Year (Part 1) | Ben Fidler | 12/17/18 | National |
| BCMA Day: At ASH ‘18, Cell Therapies For Myeloma Take Center Stage | Ben Fidler | 12/04/18 | National |
